文献速递浆细胞疾病

基于机器学习的AL淀粉样变性亚组及死亡与终末期肾病的累积发生率

Machine-learning based subgroups of AL amyloidosis and cumulative incidence of mortality and end stage kidney disease.
PubMed 文献 · Am J Hematol · 2024-09-11

本研究纳入2067例新诊断、活检证实的AL淀粉样变性患者,利用无监督机器学习基于31项临床症状和28项基线实验室指标识别出低危、中危、高危三个亚组。三组中位总生存期分别为6.1年、3.7年和1.2年,10年全因死亡调整累积发生率分别为66.8%、75.4%和90.6%。研究还训练了一个外部验证分类器,交叉验证准确率达85%。

要点

  • 机器学习识别出低危、中危、高危三个AL淀粉样变性亚组,中位总生存期分别为6.1年、3.7年和1.2年
  • 10年全因死亡调整累积发生率低危组66.8%、中危组75.4%、高危组90.6%
  • 基于易获取临床参数训练的分类器交叉验证准确率达85%(95% CI 83-86)

核心结论

  • 无监督机器学习可识别具有不同临床表型和预后的AL淀粉样变性亚组,标志着向将精准医学整合到AL淀粉样变性全因死亡和终末期肾病风险分层迈出的初步步伐。

研究设计与样本

  • 研究队列为2067例来自波士顿大学淀粉样变性中心的新诊断、活检证实的AL淀粉样变性患者,采用无监督机器学习方法,变量包括31项临床症状和28项基线实验室值。

主要发现

  • 聚类算法识别出低危、中危和高危三个亚组,中位总生存期分别为6.1年、3.7年和1.2年。
  • 10年全因死亡调整累积发生率低危组为66.8%(95% CI 63.4-70.1),中危组为75.4%(95% CI 72.1-78.6),高危组为90.6%(95% CI 87.4-93.3)。
  • 10年终末期肾病调整累积发生率低危组为20.4%(95% CI 6.1-24.5),中危组为37.6%(95% CI 31.8-43.8),高危组为6.7%(95% CI 2.8-11.3)。
  • 使用一组易获取的临床参数训练分类器进行外部验证,交叉验证准确率高(85% [95% CI 83-86])。

关键数值与推荐

  • 低危组10年全因死亡调整累积发生率为66.8%(95% CI 63.4-70.1),中危组为75.4%(95% CI 72.1-78.6),高危组为90.6%(95% CI 87.4-93.3)。
  • 低危组10年终末期肾病调整累积发生率为20.4%(95% CI 6.1-24.5),中危组为37.6%(95% CI 31.8-43.8),高危组为6.7%(95% CI 2.8-11.3)。
  • 分类器交叉验证准确率为85%(95% CI 83-86)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunoglobulin light chain (AL) amyloidosis is a multisystem disease with varied treatment options and disease-related outcomes. Current staging systems rely on a limited number of cardiac, renal, and plasma cell dyscrasia biomarkers. To improve prognostication for all-cause mortality and end-stage kidney disease (ESKD), we applied unsupervised machine learning using a comprehensive set of clinical and laboratory parameters. Our study cohort comprised 2067 patients with newly diagnosed, biopsy-proven AL amyloidosis from the Boston University Amyloidosis Center. Variables included 31 clinical symptoms and 28 baseline laboratory values. Our clustering algorithm identified three subgroups of AL amyloidosis (low-risk, intermediate-risk, and high-risk) with distinct clinical phenotypes and median overall survival (OS) estimates of 6.1, 3.7, and 1.2 years, respectively. The 10-year adjusted cumulative incidences of all-cause mortality were 66.8% (95% CI 63.4-70.1), 75.4% (95% CI 72.1-78.6), and 90.6% (95% CI 87.4-93.3) for low, intermediate, and high-risk subgroups. The 10-year adjusted cumulative incidences of end-stage kidney disease (ESKD) were 20.4% (95% CI 6.1-24.5), 37.6% (95% CI 31.8-43.8), and 6.7% (95% CI 2.8-11.3) for low-risk, intermediate-risk, and high-risk subgroups. Finally, we trained a classifier for external validation with high cross-validation accuracy (85% [95% CI 83-86]) using a subset of easily obtainable clinical parameters. This marks an initial stride toward integrating precision medicine into risk stratification of AL amyloidosis for both all-cause mortality and ESKD.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Anand SK, Staron A, Mendelson LM, et al. Machine-learning based subgroups of AL amyloidosis and cumulative incidence of mortality and end stage kidney disease. Am J Hematol. 2024. PMID: 39257247. doi:10.1002/ajh.27472

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。